You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
報道內地促藥價透明化監管機制醞釀升級
阿思達克 08-05 10:12

據《經濟參考報》報道,內地將進一步規範藥品價格管理,完善藥品價格形成機制,探索建立常態化監管機制。同時,加速推進按通用名制定醫保藥品支付標準並動態調整。報道引述權威人士透露,日前內地相關部門對現階段藥品價格管理工作,包括藥品集中採購、價格管理、醫保支付標準等方面徵求意見,意在摸清成本,促進藥品合理定價。

據悉,醫療保障部門管理價格的藥品類別包括化學藥品、中成藥、生化藥品、中藥飲片、醫院自製劑等,其中,除麻醉藥品和第一類精神藥品外,其他藥品的價格均實行市場調節。

按照要求,這些以市場定價的藥品,經營者自主制定價格時,應自覺將價格與成本、供求相匹配,自覺保持不同品規、不同區域之間價格平衡,自覺維護價格一定時期內相對穩定。同時,監管部門此次重心在藥品價格透明。未來對於藥價的管理,將通過信息的互聯互通進行比對,進行成本調查等,打破醫藥行業一直以來的數據壁壘。

此次徵求意見中透露,內地將依托省級藥品集中採購平台,建設全國藥品公共採購市場。未來將通過對藥品統一編碼、標準和功能規範,綜合運用監測預警、函詢約談、成本調查、信用評價、信息披露等手段,對藥品價格進行常態化監督。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account